REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA

Clinical trials for REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA trials appear

Sign up with your email to follow new studies for REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 7 Not yet finished but already full! 7 Completed 1 Terminated 1

Two-Drug attack tested for stubborn blood cancer

Disease control Terminated

This study tested whether combining two drugs, daratumumab and ibrutinib, works better than ibrutinib alone for patients whose chronic lymphocytic leukemia (CLL) has come back or stopped responding to previous treatments. Daratumumab helps the immune system target cancer cells, w…

Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA

Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control

Last updated Mar 23, 2026 15:15 UTC

REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA

Get alerted when new REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA trials appear

Two-Drug attack tested for stubborn blood cancer